Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions

被引：55

作者：

Papanikolaou G.N. ^{[1
]}

Baltogianni M.S. ^{[1
]}

Contopoulos-Ioannidis D.G. ^{[1
,2
]}

Haidich A.-B. ^{[1
]}

Giannakakis I.A. ^{[1
]}

Ioannidis J.P.A. ^{[1
,3
]}

机构：

[1] Clin. Trials/Evidence-Based Med. U., Dept. of Hygiene and Epidemiology, Univ. of Ioannina School of Medicine

[2] Department of Pediatrics, George Washington Univ. Sch. of Med., Washington, DC

[3] Department of Medicine, Tufts University School of Medicine, Boston, MA

来源：

BMC Medical Research Methodology | / 1卷 / 1期

关键词：

Clinical Guideline; Potential Conflict; Disclosure Policy; Disclosure Rate; Biotechnology Firm;

D O I：

10.1186/1471-2288-1-3

中图分类号：

学科分类号：

摘要：

Background: Guidelines published in major medical journals are very influential in determining clinical practice. It would be essential to evaluate whether conflicts of interests are disclosed in these publications. We evaluated the reporting of conflicts of interest and the factors that may affect such disclosure in a sample of 191 guidelines on therapeutic and/or preventive measures published in 6 major clinical journals (Annals of Internal Medicine, BMJ, JAMA, Lancet, New England Journal of Medicine, Pediatrics) in 1979, 1984, 1989, 1994 and 1999. Results: Only 7 guidelines (3.7%) mentioned conflicts of interest and all were published in 1999 (17.5% (7/40) of guidelines published in 1999 alone). Reporting of conflicts of interest differed significantly by journal (p=0.026), availability of disclosure policy by the journal (p=0.043), source of funding (p < 0.001) and number of authors (p=0.004). In the entire database of 191 guidelines, a mere 18 authors disclosed a total of 24 potential conflicts of interest and most pertained to minor issues. Conclusions: Despite some recent improvement, reporting of conflicts of interest in clinical guidelines published in influential journals is largely neglected.

引用

页码：1 / 5

页数：4

共 20 条

[1] Woolf S.H., Grol R., Hutchinson A., Eccles M., Grimshaw J., Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelines, BMJ, 318, pp. 527-530, (1999)
[2] Ioannidis J.P., Lau J., Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas, JAMA, 285, pp. 437-443, (2001)
[3] Krimsky S., Conflict of interest and cost-effectiveness analysis, JAMA, 282, pp. 1474-1475, (1999)
[4] Glass R.M., Schneiderman M., A survey of journal conflict of interest policies, Third International Congress on Peer Review in Biomedical Publications, (1997)
[5] Angell M., Utiger R.D., Wood A.J., Disclosure of authors conflicts of interest: A follow-up, N Engl J Med, 342, pp. 586-587, (2000)
[6] Wazana A., Physicians and the pharmaceutical industry: Is a gift ever just a gift?, JAMA, 283, pp. 373-380, (2000)
[7] Randall T., Kennedy hearings say no more free lunch-or much else-from drug firms, JAMA, 265, pp. 440-442, (1991)
[8] Giannakakis I., Ioannidis J.P., Arabian nights - 1001 Tales of how pharmaceutical companies cater to the material needs of doctors: Case report, BMJ, 321, pp. 1563-1564, (2000)
[9] Krimsky S., Rothenberg L.S., Stott P., Kyle G., Scientific journals and their authors' financial interests: A pilot study, Psychother Psychosom, 67, pp. 194-201, (1998)
[10] Stelfox H.T., Chua G., O'Rourke K., Detsky A.S., Conflict of interest in the debate over calcium channel antagonists, N Engl J Med, 338, pp. 101-106, (1998)

← 1 2 →